Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression.
暂无分享,去创建一个
G. Ertl | J. Bauersachs | M. Christ | M. Wehling | D. Fraccarollo | S. Hildemann | M. Heck
[1] N. Gretz,et al. Striking Increase of Natriuresis by Low-Dose Spironolactone in Congestive Heart Failure Only in Combination With ACE Inhibition: Mechanistic Evidence to Support RALES , 2000, Circulation.
[2] P. Galuppo,et al. Endothelin-receptor blockade improves endothelial vasomotor dysfunction in heart failure. , 2000, Cardiovascular research.
[3] B. Pitt,et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .
[4] D. Harrison,et al. Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. , 2000, Circulation.
[5] A. Struthers,et al. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. , 2000, Circulation.
[6] A. Takeshita,et al. Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. , 2000, Circulation research.
[7] D. Stewart,et al. Improvement of endocardial and vascular endothelial function on myocardial performance by captopril treatment in postinfarct rat hearts. , 1999, Circulation.
[8] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[9] R. Busse,et al. Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. , 1999, Circulation.
[10] D. Harrison,et al. Validation of lucigenin as a chemiluminescent probe to monitor vascular superoxide as well as basal vascular nitric oxide production. , 1999, Biochemical and biophysical research communications.
[11] R Busse,et al. NO: the primary EDRF. , 1999, Journal of molecular and cellular cardiology.
[12] H. Drexler,et al. Endothelial dysfunction in human disease. , 1999, Journal of molecular and cellular cardiology.
[13] H. Drexler,et al. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. , 1998, Circulation.
[14] H. Drexler. Endothelium as a therapeutic target in heart failure. , 1998, Circulation.
[15] J. Mehta,et al. Increased superoxide anion generation and altered vasoreactivity in rabbits on low-potassium diet. , 1998, American journal of physiology. Heart and circulatory physiology.
[16] A. Omran,et al. Increased oxidative stress in patients with congestive heart failure. , 1998, Journal of the American College of Cardiology.
[17] R. Busse,et al. Vasodilator dysfunction in aged spontaneously hypertensive rats: changes in NO synthase III and soluble guanylyl cyclase expression, and in superoxide anion production. , 1998, Cardiovascular research.
[18] H. Drexler,et al. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. , 1998, Circulation.
[19] P. Galuppo,et al. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. , 1997, Circulation.
[20] W. Linz,et al. Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats. , 1997, Hypertension.
[21] R. Busse,et al. Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production. , 1997, Hypertension.
[22] R. Ferrari,et al. Aorta and skeletal muscle NO synthase expression in experimental heart failure. , 1996, Journal of molecular and cellular cardiology.
[23] M. Ushio-Fukai,et al. p22phox Is a Critical Component of the Superoxide-generating NADH/NADPH Oxidase System and Regulates Angiotensin IIinduced Hypertrophy in Vascular Smooth Muscle Cells* , 1996, The Journal of Biological Chemistry.
[24] P. Mulder,et al. Peripheral artery structure and endothelial function in heart failure: effect of ACE inhibition. , 1996, The American journal of physiology.
[25] K. Pritchard,et al. Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure. , 1996, Circulation research.
[26] H. Drexler,et al. Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure. , 1995, The American journal of cardiology.
[27] H. Drexler,et al. Survival after myocardial infarction in the rat. Role of tissue angiotensin-converting enzyme inhibition. , 1994, Circulation.
[28] R W Alexander,et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. , 1994, Circulation research.
[29] X. Xu,et al. Defective endothelium-mediated control of coronary circulation in conscious dogs after heart failure. , 1994, The American journal of physiology.
[30] D. Hayoz,et al. Endothelial function in chronic congestive heart failure. , 1992, The American journal of cardiology.
[31] H. Drexler,et al. Endothelial dysfunction of hindquarter resistance vessels in experimental heart failure. , 1992, The American journal of physiology.
[32] M. A. Plant. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality , 1991 .
[33] B. Greenberg,et al. Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure. , 1991, Circulation research.
[34] T. Rector,et al. Endothelium‐Dependent Vasodilation Is Attenuated in Patients With Heart Failure , 1991, Circulation.
[35] J. Belch,et al. Oxygen free radicals and congestive heart failure. , 1991, British heart journal.
[36] K. Swedberg,et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.
[37] S. Whitebread,et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. , 1987, The Journal of pharmacology and experimental therapeutics.
[38] J. Staessen,et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. , 1981, The Journal of endocrinology.